Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To support further R&D and clinical study of its Oral Insulin capsule and Oral GLP1-Analog
Subscribe to our email newsletter
Oramed Pharmaceuticals has received a government grant of NIS3.1 million from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.
The grant was awarded as government participation in research and development expenses for the period of February 2009 to January 2010. The grant is subject to return according to the terms determined by the OCS.
The OCS awards grants to industries in Israel, in order to foster technological innovations. The funds will be designated and used by Oramed to support further R&D and clinical study of its Oral Insulin capsule and Oral GLP1-Analog.
Nadav Kidron Esq., CEO of Oramed Pharmaceuticals, said: We are pleased to get the support of the Office of the Chief Scientist, which demonstrates confidence in Oramed’s innovative technology. Our company looks forward to further continuing its relationship with the Office of the Chief Scientist.